Evaluating the impact of human papillomavirus vaccines

Vaccine

Volumn 27, Issue 32, 2009, Pages 4355-4362

  Chang, Yuli ^a   Brewer, Noel T ^a   Rinas, Allen C ^b   Schmitt, Karla ^c   Smith, Jennifer S ^a  

^a IL   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c FLORIDA DEPARTMENT OF HEALTH   (United States)

Author keywords

Cervical abnormalities; Cervical cancer; HPV vaccine effectiveness

Indexed keywords

WART VIRUS VACCINE;

ANUS CANCER; ARTICLE; CANCER INVASION; CLINICAL EVALUATION; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; CYTOLOGY; DRUG EFFICACY; HISTOLOGY; HUMAN; OROPHARYNX CANCER; OUTCOME ASSESSMENT; PAPANICOLAOU TEST; PAPILLOMATOSIS; PENIS CANCER; POPULATION; PRECANCER; PRIORITY JOURNAL; RECURRENT DISEASE; UTERINE CERVIX CANCER; VACCINATION; VAGINA CANCER; VIRUS INFECTION; VULVA TUMOR; WART VIRUS;

FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS;

EID: 67649513472     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.03.008     Document Type: Article

References (49)

1. Sigurdsson K. The Icelandic and Nordic cervical screening programs: trends in incidence and mortality rates through 1995. Acta Obstet Gynecol Scand 78 July (6) (1999) 478-485
2. Bosch F.X., Castellsague X., and de S.S. HPV and cervical cancer: screening or vaccination?. Br J Cancer 98 January (1) (2008) 15-21
3. Wright T.C., Bosch F.X., Franco E.L., Cuzick J., Schiller J.T., Garnett G.P., et al. Chapter 30: HPV vaccines and screening in the prevention of cervical cancer; conclusions from a 2006 workshop of international experts. Vaccine 24 August (Suppl. 3) (2006) S251-S261
4. Smith J.S., Lindsay L., Hoots B., Keys J., Franceschi S., and Winer R. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 121 August (3) (2007) 621-632
5. Schiffman M., Castle P.E., Jeronimo J., Rodriguez A.C., and Wacholder S. Human papillomavirus and cervical cancer. Lancet 370 September (9590) (2007) 890-907
6. Schiffman M., and Kjaer SK. Chapter 2: natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 31 (2003) 14-19
7. Koshiol J.E., Laurent S.A., and Pimenta J.M. Rate and predictors of new genital warts claims and genital warts-related healthcare utilization among privately insured patients in the United States. Sex Transm Dis 31 December (12) (2004) 748-752
8. Lacey C.J., Lowndes C.M., and Shah K.V. Chapter 4: burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 24 August (Suppl. 3) (2006) S35-S41
9. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356 May (19) (2007) 1915-1927
10. FUTURE II Study Group. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J Infect Dis 10 November (196) (2007) 1438-1446
11. Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364 November (9447) (2004) 1757-1765
12. Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski B., Roteli-Martins C.M., et al. Sustained efficacy up to 4 5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 April (9518) (2006) 1247-1255
13. Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., Leodolter S., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356 May (19) (2007) 1928-1943
14. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Ault K.A., Giuliano A.R., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6 May (5) (2005) 271-278
15. Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 365 May (19) (2007) 1928-1943
16. Hildesheim A., Herrero R., Wacholder S., Rodriguez A.C., Solomon D., Bratti M.C., et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 298 August (7) (2007) 743-753
17. Central for Disease Control Prevention (CDC) National vaccination coverage among adolescents aged 13-17 years-United States 2006. MMWR morbidity and mortality weekly report 2007;34(August (56)):885-8.
18. Lehtinen M., Idanpaan-Heikkila I., Lunnas T., Palmroth J., Barr E., Cacciatore R., et al. Population-based enrolment of adolescents in a long-term follow-up trial of human papillomavirus vaccine efficacy. Int J STD AIDS 17 April (4) (2006) 237-246
19. Lehtinen M., Apter D., Dubin G., Kosunen E., Isaksson R., Korpivaara E.L., et al. Enrolment of 22000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing. Int J STD AIDS 17 August (8) (2006) 517-521
20. Koshiol J., Lindsay L., Pimenta J.M., Poole C., Jenkins D., and Smith J.S. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol 168 July (2) (2008) 123-137
21. ACOG Practice Bulletin. Management of abnormal cervical cytology and histology. Clinical Management Guidelines for the Obstetrician and Gynecologist; 2005.
22. Medeiros F., Yuan L., Breslin G., Brodsky J., Saleemuddin A., Feldman S., et al. Type-specific HPV testing as a predictor of high-grade squamous intraepithelial lesion outcome after cytologic abnormalities. J Low Genit Tract Dis 9 July (3) (2005) 154-159
23. Schneider A., Hoyer H., Lotz B., Leistritza S., Kuhne-Heid R., Nindl I., et al. Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy. Int J Cancer 89 November (6) (2000) 529-534
24. Solomon D., Schiffman M., and Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst 93 February (4) (2001) 293-299
25. Cox J.T. Human papillomavirus testing in primary cervical screening and abnormal Papanicolaou management. Obstet Gynecol Surv 61 June (6 Suppl. 1) (2006) S15-S25
26. Paavonen J., Jenkins D., Bosch F.X., Naud P., Salmeron J., Wheeler C.M., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369 June (9580) (2007) 2161-2170
27. Koshiol J., Lindsay L., Pimenta J.M., Poole C., Jenkins D., and Smith J.S. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol 168 July (2) (2008) 123-137
28. Sellors JW, Lorincz AT, Mahony JB, Mielzynska I, Lytwyn A, Roth P, et al. Comparison of self-collected vaginal, vulvar and urine samples with physician-collected cervical samples for human papillomavirus testing to detect high-grade squamous intraepithelial lesions. CMAJ 2000;163(September (5)):513-8.
29. Cuschieri K.S., Cubie H.A., Whitley M.W., Gilkison G., Arends M.J., Graham C., et al. Persistent high risk HPV infection associated with development of cervical neoplasia in a prospective population study. J Clin Pathol 58 September (9) (2005) 946-950
30. Schiffman M., and Solomon D. Findings to date from the ASCUS-LSIL Triage Study (ALTS). Arch Pathol Lab Med 127 August (8) (2003) 946-949
31. Clifford G.M., Rana R.K., Franceschi S., Smith J.S., Gough G., and Pimenta J.M. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomark Prev 14 May (5) (2005) 1157-1164
32. ASCUS-LSIL Traige Study (ALTS) Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 188 June (6) (2003) 1383-1392
33. Stoler M.H., and Schiffman M. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA 285 March (11) (2001) 1500-1555
34. Smith-McCune K., and Sawaya G.F. HPV vaccination-more answers, more questions. N Engl J Med 356 May (19) (2007) 1991-1993
35. Chang A.R. Carcinoma in situ of the cervix and its malignant potential. A lesson from New Zealand. Cytopathology 1 6 (1990) 321-328
36. Plummer M., and Franceschi S. Strategies for HPV prevention. Virus Res 89 November (2) (2002) 285-293
37. Lacey C.J. Therapy for genital human papillomavirus-related disease. J Clin Virol 32 March (Suppl. 1) (2005) S82-S90
38. Vandepapeliere P., Barrasso R., Meijer C.J., Walboomers J.M., Wettendorff M., Stanberry L.R., et al. Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination. J Infect Dis 192 December (12) (2005) 2099-2107
39. Dinh T.H., Sternberg M., Dunne E.F., and Markowitz L.E. Genital warts among 18- to 59-year-olds in the United States, national health and nutrition examination survey 1999-2004. Sex Transm Dis 35 April (4) (2008) 357-360
40. Tasca R.A., and Clarke R.W. Recurrent respiratory papillomatosis. Arch Dis Child 91 August (8) (2006) 689-691
41. Joura E.A., Leodolter S., Hernandez-Avila M., Wheeler C.M., Perez G., Koutsky L.A., et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 369 May (9574) (2007) 1693-1702
42. Gillison M.L., and Shah K.V. Chapter 9: role of mucosal human papillomavirus in nongenital cancers. J Natl Cancer Inst Monogr 31 (2003) 57-65
43. Hoots B.E., Palefsky J.M., Pimenta J.M., and Smith J.S. Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int J Cancer 124 December (10) (2008) 2375-2383
44. Smith J.S., Backes D.M., Hoots B.E., Kurman R.J., and Pimenta J.M. Human Papillomavirus Type-Distribution in Vulvar and Vaginal Cancers and Their Associated Precursors. Obstet Gynecol 113 April (4) (2009) 917-924
45. Backes DM, Kurman RJ, Pimenta JM, Smith JS. Systematic review of human papillomavirus prevalence in invasive penile cancer. Cancer Causes Control 2008; December 11.
46. Kreimer A.R., Clifford G.M., Boyle P., and Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 14 February (2) (2005) 467-475
47. SEER Cancer Statistics review, 1975-2004, based on November 2006 SEER data submission, posted to the SEER web site, 2007. Bethesda (MD): National Cancer Institute; 2007.
48. US Department of Health Human Services. Healthy people 2010 (2000), US Department of Health and Human Services
49. Vaccination coverage among adolescents aged 13-17 years-United States, 2007. Morbidity and mortality weekly report; 2008 October.